11th Annual Conference Of The British HIV Association [BHIVA] 20–23 April 2005, Burlington Hotel·Dublin·Ireland

[AUTHOR(S):] D Pao¹, K Aderogba¹, G Dean¹, P Cane², E Smit³, D Pillay⁴ and M Fisher^1
1Dept of GU Medicine, Brighton and Sussex University Hospitals, UK, ²Health Protection Agency, Porton Down, UK, ³Health Protection Agency, Birmingham, UK, ⁴Health Protection Agency, Colindale, UK

BHIVA Conf 2005 Apr 20-23;11:O17

BACKGROUND: It is well recognised that a significant minority of individuals with primary HIV infection (PHI) harbour transmitted antiretroviral resistance (TAR). Whilst most clinicians perform resistance testing in individuals diagnosed with PHI, only 6% diagnosed with non-PHI were tested pre-treatment in the 2002/3 BHIVA audit, despite guidelines to the contrary.

OBJECTIVES: To compare trends in prevalence of genotypic TAR among individuals diagnosed at PHI and non-PHI.

METHODS: Analysis of TAR (including only major, significant mutations) in 450 treatment-naïve individuals, classified as PHI or non-PHI by year of diagnosis, from 2000–2004.

RESULTS: Genotype results were available in 147/149 (99%) and 127/301 (42%) of the PHI and non-PHI group respectively. To account for possible testing bias in non-PHI, re-analysis assuming no resistance in those untested (58%) is shown(1).

CONCLUSIONS: TAR remains of significant clinical importance despite high levels of effective viral suppression. We demonstrate that rates remain stable and furthermore are comparable in individuals diagnosed at non-PHI as well as PHI. All new HIV diagnoses should have baseline resistance testing performed irrespective of time since infection.

PRESENTING AUTHOR: K Aderogba

Download Presentation

2005-04-20
xx

Copyright © 2005 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD